mnkdnyc
Lab Rat
Posts: 48
Sentiment: Long
|
Post by mnkdnyc on Apr 2, 2014 2:31:31 GMT -5
Cowen and Co. comes out with a downgrade and a $5 target from $5.50. Weasels.
|
|
|
|
Post by liane on Apr 2, 2014 5:08:36 GMT -5
Seriously??
|
|
|
|
Post by liane on Apr 2, 2014 5:14:39 GMT -5
|
|
|
|
Post by BD on Apr 2, 2014 6:44:19 GMT -5
And Piper is at least being consistent:
05:53 EDT MNKD theflyonthewall.com: Panel raised questions about Afrezza's commercial outlook, says Piper Jaffray
Piper Jaffray believes the issues discussed as yesterday's FDA panel meeting raise questions regarding the commercial outlook for Afrezza. Piper believes FDA approval of the drug "seems inevitable" with yesterday's positive vote, but it sees challenges ahead and raised its price target for MannKind shares to only $2.00 from $1.50. It keeps an Underweight rating on the stock. :theflyonthewall.com
|
|
|
|
Post by BD on Apr 2, 2014 6:46:08 GMT -5
BofA too! Looks like lots of short covering still has to happen!
06:36 EDT MNKD theflyonthewall.com: MannKind continues to have partnering risks, says BofA/Merrill
BofA/Merrill expects MannKind's inhaled insulin to be approved but with a restrictive label that will deter any strong partnership interest. The firm reiterates its Underperform rating and $4 price target. :theflyonthewall
|
|
|
|
Post by BD on Apr 2, 2014 6:47:39 GMT -5
So compared to the previous few, JPM's outlook is positively glowing!:
07:33 EDT MNKD theflyonthewall.com: MannKind shares may 'overshoot to the upside,' says JPMorgan
JPMorgan believes shares of MannKind may "overshoot to the upside" following the positive FDA panel vote given the significant short interest in the name as well as the company’s "passionate" retail following. JPMorgan remains concerned about the commercial potential of Afrezza and keeps a Neutral rating on MannKind. :theflyonthewall
|
|
|
|
Post by silentbob on Apr 2, 2014 6:51:19 GMT -5
Cowen and Co. comes out with a downgrade and a $5 target from $5.50. Weasels. Well obviously the nearly unanimous positive vote is bad news for Mannkind. How could we have missed that. |
|
|
|
Post by ezrasfund on Apr 2, 2014 6:57:43 GMT -5
Pre-Market trading is at a blistering pace considering that it's still before 8 AM. Already 1,900,000 shares traded with the price hovering around $8. I expect record volume of at least 30 million share today and some interesting price action. Will it find a level and hold a relatively tight range or spike wildly up and down in the usual MNKD way?
I slept soundly before the AdCom, but now I'm much more restless, knowing I have to trim my position and take profits. Not much to decide on Monday but to hold tight. Today I have to decide where to start selling. I put in one sell order at $9.50, but where she stops, nobody knows.
|
|
|
|
Post by liane on Apr 2, 2014 7:02:43 GMT -5
The anal-ysts are right on cue.
|
|
|
|
Post by babaoriley on Apr 2, 2014 8:27:02 GMT -5
All to be expected. Also, consider this: if you are short, and do not have a margin call or otherwise forced to cover, you're going to seriously consider holding and not covering quite yet, and possibly all the way through PDUFA. The stock should be valued almost as if it got the approval, so the thinking is that there will not be a significant bump on approval (of course, depending on what the price is right before), so hold, see if the price comes down (likely will), perhaps cover a bit then, and then take a chance that the FDA screws us.
Most shorts will not panic buy today. By the way, does anyone know the short interest as of end of Monday?
|
|
|
|
Post by 4allthemarbles on Apr 2, 2014 9:01:34 GMT -5
Baba- you think the shorts will wait to cover?
|
|
|
|
Post by babaoriley on Apr 2, 2014 9:26:40 GMT -5
It's a continuum, some will, some won't. Many covered Monday, more in AH yesterday and some this morning, the more panicky ones, or the ones that had to due to margin.
|
|
|
|
Post by mnkdwillwin on Apr 2, 2014 10:56:19 GMT -5
I heard 63 million and we have surpassed that in trading already today
|
|
